"Arming" the chimeric oncolytic adenovirus enadenotucirev to deliver checkpoint inhibitors and other therapeutics directly to tumours

Overview of attention for article published in Journal for Immunotherapy of Cancer, November 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (76th percentile)
Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

patent: 3 patents

Readers on

mendeley: 3 Mendeley

Summary Patents

So far, Altmetric has seen 3 patents that reference this research output.

ADENOVIRUS ARMED WITH BISPECIFIC T CELL ENGAGER (BITE)

Application EP-4273252-A3

European Patent Office

ADENOVIRUS ARMED WITH BISPECIFIC T CELL ENGAGER (BITE)

Application WO-2018041827-A1

World Intellectual Property Organisation (WIPO)

ADENOVIRUS ARMED WITH BISPECIFIC T CELL ENGAGER (BITE)

Application WO-2018041838-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.